GDF11 Protein Shields Kidneys from Sepsis Damage via PGC-1α/Nrf2 Pathway
A growth factor naturally upregulated in sepsis reduces kidney injury by activating antioxidant defenses and curbing inflammation and clotting.
Summary
Researchers found that growth differentiation factor 11 (GDF11) is naturally elevated in the kidneys of mice with sepsis-associated acute kidney injury (SAKI). Silencing GDF11 worsened kidney function, tubular damage, and cell death, while supplementing recombinant GDF11 reversed these effects. Mechanistically, GDF11 activates the transcriptional coactivator PGC-1α, which in turn boosts Nrf2-driven antioxidant defenses, dampening excessive inflammation and pathological coagulation. Blocking either PGC-1α or Nrf2 abolished GDF11's protective benefits. These findings identify GDF11 as a promising therapeutic candidate for SAKI and clarify a previously unexplored molecular pathway underlying its kidney-protective actions.
Detailed Summary
Sepsis-associated acute kidney injury (SAKI) affects up to 60% of ICU patients with sepsis and carries a mortality rate of 20–30%, yet effective pharmacological treatments remain elusive. This study investigated whether growth differentiation factor 11 (GDF11), a TGF-β superfamily member with emerging anti-inflammatory properties, could protect the kidneys during sepsis and, if so, through what molecular mechanism.
Using cecal ligation and puncture (CLP) surgery in C57BL/6J mice to model severe sepsis, the researchers first documented that GDF11 is markedly upregulated in renal tubular epithelial cells and macrophages during SAKI. To test causality, they delivered adeno-associated virus (AAV2) shRNA constructs via tail vein injection to silence GDF11 specifically in the kidney three weeks before CLP. GDF11 knockdown significantly worsened renal dysfunction (elevated creatinine and BUN), increased tubular histological damage, amplified apoptosis, and exacerbated pro-inflammatory and pro-coagulant markers. Conversely, intraperitoneal administration of recombinant GDF11 (rGDF11, 250 or 500 µg/kg) post-CLP markedly attenuated all these parameters in a dose-dependent manner. Parallel LPS-stimulated experiments in TCMK-1 tubular epithelial cells and Raw264.7 macrophages confirmed the in vivo findings.
RNA sequencing of kidney tissue, combined with Western blot, RT-qPCR, and ELISA assays, revealed that GDF11 upregulates PGC-1α expression. PGC-1α subsequently elevates nuclear Nrf2 levels, driving expression of antioxidant enzymes including HO-1 and NQO-1, while suppressing NF-κB-mediated production of TNF-α, IL-6, and IL-1β. GDF11 treatment also reduced coagulation markers—tissue factor (TF), fibrinogen, PAI-1, thrombin-antithrombin complex (TAT), and D-dimer—that are hallmarks of sepsis-induced coagulopathy. Oxidative stress indicators (MDA, ROS) were lowered, while antioxidant enzyme activity (SOD, GSH-Px, CAT) was restored.
Critically, AAV2-mediated knockdown of PGC-1α or genetic knockout of Nrf2 largely abolished rGDF11's protective effects in CLP mice, establishing the PGC-1α→Nrf2 axis as the primary effector pathway. The study also confirmed macrophage polarization benefits, with GDF11 shifting macrophages toward an anti-inflammatory M2 phenotype (increased CD206, reduced CD86, iNOS).
These findings position GDF11 as both a natural kidney-protective response factor and a viable exogenous therapeutic for SAKI. The PGC-1α/Nrf2 signaling axis represents a tractable pharmacological target. Limitations include the exclusive use of male mice, reliance on a single CLP model, and the absence of human clinical validation, warranting further translational investigation.
Key Findings
- GDF11 is naturally upregulated in renal tubular cells and macrophages during CLP-induced septic AKI in mice.
- AAV-mediated GDF11 knockdown worsened kidney dysfunction and tubular damage; recombinant GDF11 reversed these effects dose-dependently.
- GDF11 activates PGC-1α, which elevates nuclear Nrf2 and boosts antioxidant enzymes (HO-1, NQO-1), reducing oxidative stress.
- GDF11 suppressed key inflammatory cytokines (TNF-α, IL-6, IL-1β) and coagulation markers (TF, fibrinogen, D-dimer, PAI-1).
- Knockdown of PGC-1α or Nrf2 knockout abolished GDF11's kidney-protective benefits, confirming the PGC-1α/Nrf2 pathway is essential.
Methodology
Male C57BL/6J mice underwent cecal ligation and puncture (CLP) to model SAKI; AAV2 shRNA was used for kidney-targeted gene silencing of GDF11 and PGC-1α. Mechanistic studies employed RNA sequencing, Western blot, RT-qPCR, ELISA, TUNEL, and antioxidant enzyme assays, with Nrf2 knockout mice and LPS-stimulated cell lines (TCMK-1, Raw264.7) for in vitro validation.
Study Limitations
The study used only male mice and a single CLP sepsis model, limiting generalizability across sexes and sepsis etiologies. No human SAKI tissue data or clinical pharmacokinetic data for rGDF11 were presented, leaving a substantial translational gap before clinical application.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.